Renaud Tissier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Renaud Tissier has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Daniela S. Thommen
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands
19 shared publications - Diane Damotte
Université Paris Cité, APHP
19 shared publications - Egbert Frederik Smit
Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands
19 shared publications - François Goldwasser
Department of Medical Oncology, Cochin Hospital, Institut du Cancer Paris CARPEM, Université Paris Cité, AP-HP, Paris, France
19 shared publications - Gerrit A. Meijer
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
19 shared publications - Karen Leroy
Paris Cité University, Molecular Biology Department, Georges Pompidou European Hospital, AP-HP, Paris, France
19 shared publications
Latest Publications
- Open Access
- 19 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (10) , 1846-1856
Risk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants
Background: Over the past decade, various large observational studies have suggested an association between silicone breast implants (SBIs) and autoimmune and rheumatic diseases (ARDs), rekindling long-standing breast implant-safety concerns among breast cancer survivors with breast reconstructions and newly diagnosed breast cancer patients. Methods: We investigated the association between SBIs and ARDs in a large multicenter cohort of women treated for breast cancer, part of whom received SBIs for reconstructive purposes. Clinical data and events of interest were identified through linkages with prospectively maintained nationwide- and institutional registries. Hazard Ratios (HRs) for ARDs were calculated using Cox proportional hazards regression models adjusted for potential confounders. Results: Of 12,262 women in the cohort, 3,082 (25%) had received SBI-based breast reconstructions. Median follow-up time was 12.0 (IQR, 7.0) years. The event rate of ARD-diagnoses was 62.5 per 10,000 person-years. Compared with women without SBI-exposure, women with an implant-based breast reconstruction did not have an increased risk of ARDs (multivariably adjusted HR, 1.06, 95% CI [0.89 to 1.27]). In addition, no statistically significant association was found between SBI-exposure and inflammatory arthritis, systematic rheumatic disease, inflammatory dermatosis, inflammatory bowel disease or any specific condition. Sensitivity analyses in which SBI-exposure was analyzed as a time-dependent variable confirmed the results of the main analysis. Conclusion: The findings of this study indicate that SBI-exposure is not associated with an increased risk of ARDs in women with breast cancer and challenge the results of earlier studies in women with cosmetic implants. Registration: This study is registered at ClinicalTrials.gov on June 2nd 2022 (NCT05400954)
- 19 April 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (10) , 1846-1856
Open AccessRisk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants
Background: Over the past decade, various large observational studies have suggested an association between silicone breast implants (SBIs) and autoimmune and rheumatic diseases (ARDs), rekindling long-standing breast implant-safety concerns among breast cancer survivors with breast reconstructions and newly diagnosed breast cancer patients. Methods: We investigated the association between SBIs and ARDs in a large multicenter cohort of women treated for breast cancer, part of whom received SBIs for reconstructive purposes. Clinical data and events of interest were identified through linkages with prospectively maintained nationwide- and institutional registries. Hazard Ratios (HRs) for ARDs were calculated using Cox proportional hazards regression models adjusted for potential confounders. Results: Of 12,262 women in the cohort, 3,082 (25%) had received SBI-based breast reconstructions. Median follow-up time was 12.0 (IQR, 7.0) years. The event rate of ARD-diagnoses was 62.5 per 10,000 person-years. Compared with women without SBI-exposure, women with an implant-based breast reconstruction did not have an increased risk of ARDs (multivariably adjusted HR, 1.06, 95% CI [0.89 to 1.27]). In addition, no statistically significant association was found between SBI-exposure and inflammatory arthritis, systematic rheumatic disease, inflammatory dermatosis, inflammatory bowel disease or any specific condition. Sensitivity analyses in which SBI-exposure was analyzed as a time-dependent variable confirmed the results of the main analysis. Conclusion: The findings of this study indicate that SBI-exposure is not associated with an increased risk of ARDs in women with breast cancer and challenge the results of earlier studies in women with cosmetic implants. Registration: This study is registered at ClinicalTrials.gov on June 2nd 2022 (NCT05400954)
- Open Access
- 3 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1717-1728
Breast implant illness after reconstruction with silicone breast implants
Background: “Breast implant illness” (BII) is a constellation of non-specific constitutional, rheumatologic, mental, and cognitive symptoms reported increasingly by women carrying silicone breast implants (SBIs). The impact of BII on the well-being of breast cancer patients with SBI-based breast reconstructions is a subject of debate. Methods: In a multicenter cohort of breast cancer survivors (n = 9590) treated between 2000 and 2015 in 6 major regional hospitals in the Netherlands, we performed a health survey (response rate 64.7%). The presence of 18 BII-associated symptoms was compared between patients with and without SBIs in multivariable logistic regression models. In a latent class analysis (LCA), distinct symptom patterns were identified in the study population. Results: Median follow-up time was 13.7 (IQR, 6.8) years. Of all SBI-exposed patients (n = 1821), 20.7% reported ≥4 BII-associated symptoms vs 21.2% of non-exposed patients (risk ratio 0.98; 95% CI = 0.88 to 1.09). Joint pain, sicca, sleep impairment, morning stiffness, and shoulder pain were reported most frequently. Patients with SBIs did not have a significantly increased risk of any of the individual BII-associated symptoms. The LCA identified 5 distinct symptom clusters. Patients with SBI-exposure had a lower risk of falling in the most severe symptom cluster (odds ratio 0.64; 95% CI = 0.43 to 0.96). The other symptom clusters were not significantly associated with SBI-exposure. Conclusions: Our results indicate that breast cancer survivors with SBI-based reconstructions do not experience more BII-associated symptoms than breast cancer survivors without SBIs, challenging the notion of BII as a distinct clinical entity based on a generic silicone-induced biomechanical pathophysiological mechanism. Trial registration: This study was preregistered at ClinicalTrials.gov on June 2, 2022 (NCT05400954).
- 3 July 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1717-1728
Open AccessBreast implant illness after reconstruction with silicone breast implants
Background: “Breast implant illness” (BII) is a constellation of non-specific constitutional, rheumatologic, mental, and cognitive symptoms reported increasingly by women carrying silicone breast implants (SBIs). The impact of BII on the well-being of breast cancer patients with SBI-based breast reconstructions is a subject of debate. Methods: In a multicenter cohort of breast cancer survivors (n = 9590) treated between 2000 and 2015 in 6 major regional hospitals in the Netherlands, we performed a health survey (response rate 64.7%). The presence of 18 BII-associated symptoms was compared between patients with and without SBIs in multivariable logistic regression models. In a latent class analysis (LCA), distinct symptom patterns were identified in the study population. Results: Median follow-up time was 13.7 (IQR, 6.8) years. Of all SBI-exposed patients (n = 1821), 20.7% reported ≥4 BII-associated symptoms vs 21.2% of non-exposed patients (risk ratio 0.98; 95% CI = 0.88 to 1.09). Joint pain, sicca, sleep impairment, morning stiffness, and shoulder pain were reported most frequently. Patients with SBIs did not have a significantly increased risk of any of the individual BII-associated symptoms. The LCA identified 5 distinct symptom clusters. Patients with SBI-exposure had a lower risk of falling in the most severe symptom cluster (odds ratio 0.64; 95% CI = 0.43 to 0.96). The other symptom clusters were not significantly associated with SBI-exposure. Conclusions: Our results indicate that breast cancer survivors with SBI-based reconstructions do not experience more BII-associated symptoms than breast cancer survivors without SBIs, challenging the notion of BII as a distinct clinical entity based on a generic silicone-induced biomechanical pathophysiological mechanism. Trial registration: This study was preregistered at ClinicalTrials.gov on June 2, 2022 (NCT05400954).
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression signature, summary of training and validation results.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression signature, summary of training and validation results.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Predictive accuracy of PDCD1 gene expression.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Coefficients of the PD-1T signature genes used in the prediction model.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Coefficients of the PD-1T signature genes used in the prediction model.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Data from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Purpose:Because PD-1 blockade is only effective in a minority of patients with advanced-stage non–small cell lung cancer (NSCLC), biomarkers are needed to guide treatment decisions. Tumor infiltration by PD-1T tumor-infiltrating lymphocytes (TIL), a dysfunctional TIL pool with tumor-reactive capacity, can be detected by digital quantitative IHC and has been established as a novel predictive biomarker in NSCLC. To facilitate translation of this biomarker to the clinic, we aimed to develop a robust RNA signature reflecting a tumor's PD-1T TIL status.Experimental Design:mRNA expression analysis using the NanoString nCounter platform was performed in baseline tumor samples from 41 patients with advanced-stage NSCLC treated with nivolumab that were selected on the basis of PD-1T TIL infiltration by IHC. Samples were included as a training cohort (n = 41) to develop a predictive gene signature. This signature was independently validated in a second cohort (n = 42). Primary outcome was disease control at 12 months (DC 12 m), and secondary outcome was progression-free and overall survival.Results:Regularized regression analysis yielded a signature using 12 out of 56 differentially expressed genes between PD-1T IHC-high tumors from patients with DC 12 m and PD-1T IHC-low tumors from patients with progressive disease (PD). In the validation cohort, 6/6 (100%) patients with DC 12 m and 23/36 (64%) with PD were correctly classified with a negative predictive value (NPV) of 100% and a positive predictive value of 32%.Conclusions:The PD-1T mRNA signature showed a similar high sensitivity and high NPV as the digital IHC quantification of PD-1T TIL. This finding provides a straightforward approach allowing for easy implementation in a routine diagnostic clinical setting.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Purpose:Because PD-1 blockade is only effective in a minority of patients with advanced-stage non–small cell lung cancer (NSCLC), biomarkers are needed to guide treatment decisions. Tumor infiltration by PD-1T tumor-infiltrating lymphocytes (TIL), a dysfunctional TIL pool with tumor-reactive capacity, can be detected by digital quantitative IHC and has been established as a novel predictive biomarker in NSCLC. To facilitate translation of this biomarker to the clinic, we aimed to develop a robust RNA signature reflecting a tumor's PD-1T TIL status.Experimental Design:mRNA expression analysis using the NanoString nCounter platform was performed in baseline tumor samples from 41 patients with advanced-stage NSCLC treated with nivolumab that were selected on the basis of PD-1T TIL infiltration by IHC. Samples were included as a training cohort (n = 41) to develop a predictive gene signature. This signature was independently validated in a second cohort (n = 42). Primary outcome was disease control at 12 months (DC 12 m), and secondary outcome was progression-free and overall survival.Results:Regularized regression analysis yielded a signature using 12 out of 56 differentially expressed genes between PD-1T IHC-high tumors from patients with DC 12 m and PD-1T IHC-low tumors from patients with progressive disease (PD). In the validation cohort, 6/6 (100%) patients with DC 12 m and 23/36 (64%) with PD were correctly classified with a negative predictive value (NPV) of 100% and a positive predictive value of 32%.Conclusions:The PD-1T mRNA signature showed a similar high sensitivity and high NPV as the digital IHC quantification of PD-1T TIL. This finding provides a straightforward approach allowing for easy implementation in a routine diagnostic clinical setting.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
PD-1T quantification by an algorithm-based immunohistochemical (IHC) imaging approach.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Patient characteristics and treatment outcomes for training and validation cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear association tests.
- Open Access
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Overview of significantly expressed genes between tumors from PD-1T IHC high patients (n=12) and PD-1T IHC low patients (n=29).
- 16 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Overview of significantly expressed genes between tumors from PD-1T IHC high patients (n=12) and PD-1T IHC low patients (n=29).